Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-81
- Development stage
- Preclinical
- Lead developer
- Corellia AI
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PSMA-81 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Corellia AI for the treatment of prostate cancer. Utilizing Corellia's proprietary Coromip technology, PSMA-81 features a dual-targeting mechanism that binds to both prostate-specific membrane antigen (PSMA) and CD180 on the surface of cancer cells. This specific targeting allows for the selective delivery of its cytotoxic payload, the PI3K/mTOR inhibitor omipalisib (also known as compound '81'), directly into the tumor microenvironment. By combining the precision of antibody-mediated delivery with the potent kinase inhibition of omipalisib, PSMA-81 is designed to maximize therapeutic efficacy while reducing systemic toxicity. The drug is currently in the discovery and in vivo stages of preclinical development.
- Other names
- Coromip
02
Targets
PSMA (Prostate-specific membrane antigen)CD180 (CD180 molecule)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on PSMA-81.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-81.